Cyclopharm Limited (AU:CYC) has released an update.
Cyclopharm Limited has successfully doubled its Share Purchase Plan (SPP) goal, raising $4 million due to substantial shareholder support, following a $20 million raise from institutional investors. The Australian radiopharmaceutical company is now fully funded to expand the manufacture and sales of its flagship product, Technegas®, which has recently received USFDA approval and reimbursement authorization. The new shares will be issued at $1.42 each, enhancing the company’s capacity to seize growth opportunities.
For further insights into AU:CYC stock, check out TipRanks’ Stock Analysis page.
